Αποτελέσματα Αναζήτησης
It is unusual for children to require second-line drugs, except for the occasional use of systemic corticosteroids for very severe, acute exacerbations of chronic urticaria. Second-line drugs should be used with considerable care in pregnancy. Doxepin is a tricyclic antidepressant with very potent H-1 and H-2 antihistaminic properties.
- Doxepin in children and adolescents with symptoms of insomnia: a single ...
This is a retrospective single-center chart review of...
- Doxepin in children and adolescents with symptoms of insomnia: a single ...
First-generation antihistamines (fgAHs) remain commonly used in pediatric CSU treatment despite a lack of studies assessing their efficacy and safety in the pediatric population and their widely known inferior safety profile compared to sgAHs.
14 Φεβ 2024 · Doxepin is listed as a potentially inappropriate medicine, which should be avoided in patients aged 65 and older by the American Geriatric Society and Beers criteria. However, the usual starting dose in older patients should be the low end of the dosing range as they have a greater probability of decreased hepatic, renal, or cardiac functions.
8 Ιουν 2021 · Doxepin helps for itching and hives. However, Doxepin causes some strong side effects and thus it should be taken with caution. Doxepine is at the same time a tricyclic antidepressant medical drug and a powerful antihistamine medical drug.
Medical uses. Doxepin is used as a pill to treat major depressive disorder, anxiety disorders, and chronic hives, and for short-term help with trouble remaining asleep after going to bed (a form of insomnia). [10][7][11] As a cream it is used for short-term treatment of itchiness caused by atopic dermatitis or lichen simplex chronicus. [13]
Pediatric. Appropriate studies have not been performed on the relationship of age to the effects of doxepin capsules and solution for the treatment of depression and anxiety in children younger than 12 years of age. Safety and efficacy have not been established.
5 Μαΐ 2020 · This is a retrospective single-center chart review of children and adolescents (2–17 years of age) whose sleep failed to improve with behavioral intervention and melatonin who were then trialed on doxepin.
